A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer

Trial Profile

A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs Panitumumab (Primary) ; Cetuximab
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ASPECCT
  • Sponsors Amgen
  • Most Recent Events

    • 13 Jun 2018 Results of a biomarker analysis published in the Clinical Cancer Research.
    • 20 Jan 2018 Results of a pooled analysis in a subgroup of patients with prior bevacizumab from the ASPECCT and WJOG6510G trials (n=374) presented at the 2018 Gastrointestinal Cancers Symposium
    • 26 Oct 2017 Results of analysis exploring the mutations in EGFR pathway genes and their association with outcomes presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top